Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript

SA Transcripts159.07K FollowersFollow5ShareSaveComments Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call March 20, 2026 8:30 AM EDT Company Participants Kathy YuAnkang Li - Chief Financial & Strategy Officer, Joint Secretary and Executive DirectorDavid Margolis - Chief Medical Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Presentation Kathy Yu [Audio Gap] Please be advised that today's call is being recorded. This call will be conducted in English. This is Kathy Yu, Associate Director of Investor Relations. Welcome to Brii Bio's 2025 Full Year Financial Results and Corporate Update Conference Call. Our annual result announcements can be found on the Investor Relations section of our company website. Before we start, I would like to remind everyone that today's call may contain forward-looking statements which involve several risks and uncertainties. Actual results and outcome may differ materially from those mentioned in today's announcement and this discussion. In addition, any forward-looking statements present our view only as of the date of this call and should not be relied upon as representing our view as of any subsequent date. We specifically disclaim any obligation to update such statements. Joining us today on the call from Brii Bio's corporate executive team are Dr. Ankang Li, Chief Operating Officer; and Dr. David Margolis, Chief Medical Officer. Dr. Li recently transitioned from our Chief Strategy and Financial Officer to Chief Operating Officer, expanding his responsibilities to further strengthen operational execution across the organization. Leveraging both on his operational leadership and scientific background, he will also support the advancement of our R&D programs while continuing to enhance our operation in China. This transition allows Dr. Hong, our CEO, to remain focused on the company's strategic priorities, scientific directions and long-term development. Meanwhile, Dr. Qing Zhu transitioned from Head of China R&D to Head of Preclinical Science and